Matilon

MAT / HOMEPAGE / 01

SCHEMA v3.2

SECTION 01 / STATEMENT

Decide What's Next in Biomanufacturing Systems

Matilon is a research boutique providing proprietary intelligence on biomanufacturing systems to select senior executives responsible for multi-year process architecture and industrialization decisions.

InquiryCorporate Access

CLASSIFICATION · CANONICAL

REC.MAT.HOME.001

RELIED ON ACROSS BIOMANUFACTURING AND INDUSTRIALIZATION EXECUTIVE FUNCTIONS

2 SEGMENTS

Biopharma · CDMOs

02 / SERVICES

03 / RECENT ISSUANCES

Recent Issuances

ISSUANCE TIMELINE · 52 WEEKS

2025-W41 – 2026-W41

Q4 2025

12 ISSUED · 1 NONE

Q1 2026

12 ISSUED

Q2 2026

13 ISSUED

Q3 2026

14 ISSUED

NEXT

DUE

ISSUED · 51NO ISSUANCE · DEC 24–30SCHEDULED · MT-2026-10-07-V1
No.
Record ID
Week
Issued
Schema
Entries
Access
Status
Preceding
01
MT-2026-10-07-V1
2026-W41
2026-10-07
3.2
4–8
EXECUTIVE
SCHEDULED
MT-2026-09-30-V1
02
MT-2026-09-30-V1
2026-W40
2026-09-30
3.2
4–8
EXECUTIVE
FINALIZED
MT-2026-09-23-V1
03
MT-2026-09-23-V1
2026-W39
2026-09-23
3.2
4–8
EXECUTIVE
FINALIZED
MT-2026-09-16-V1
04
MT-2026-09-16-V1
2026-W38
2026-09-16
3.2
4–8
EXECUTIVE
FINALIZED
MT-2026-09-09-V1
05
MT-2026-09-09-V1
2026-W37
2026-09-09
3.2
4–8
EXECUTIVE
FINALIZED
MT-2026-09-02-V1
06
MT-2026-09-02-V1
2026-W36
2026-09-02
3.2
4–8
EXECUTIVE
FINALIZED
MT-2026-08-26-V1
07
MT-2026-08-26-V1
2026-W35
2026-08-26
3.2
4–8
EXECUTIVE
FINALIZED
MT-2026-08-19-V1
08
MT-2026-08-19-V1
2026-W34
2026-08-19
3.2
4–8
EXECUTIVE
FINALIZED
MT-2026-08-12-V1
09
MT-2026-08-12-V1
2026-W33
2026-08-12
3.2
4–8
EXECUTIVE
FINALIZED
MT-2026-08-05-V1

8 RECORDS · 1 SCHEDULED · RETAINED UNDER APPEND-ONLY GOVERNANCE

View full index →

04 / SPECIMEN

Record Specimen

Each Matilon Research issuance is a single canonical record, distributed as an issued PDF/A-2b document and as HTML and structured text for programmatic ingestion.

MT-2026-02-18-V1.pdfapplication/pdf · PDF/A-2b
MT-2026-02-18-V1.htmltext/html; charset=UTF-8 · 144 LINES · 9.8 KB
1
<!DOCTYPE html>
2
<html lang="en">
3
<head>
4
<meta charset="UTF-8">
5
<meta name="schema-version" content="3.2">
6
<title>MT-2026-02-18-V1</title>
7
</head>
8
<body>
9
<header class="matilon-research">
10
<h1>MATILON RESEARCH</h1>
11
</header>
12
<section data-section="record-control">
13
<h2>RECORD_CONTROL</h2>
14
<dl>
15
<dt>TYPE:</dt><dd>INTELLIGENCE</dd>
16
<dt>RECORD_ID:</dt><dd>MT-2026-02-18-V1</dd>
17
<dt>PRECEDING_RECORD:</dt><dd>MT-2026-02-11-V1</dd>
18
<dt>RECORD_SIGNATURE:</dt><dd>7A2E9C4F-3B81-4D56-A9E3-2F7C8B1D5E04</dd>
19
<dt>VERSION:</dt><dd>1.0</dd>
20
<dt>STATUS:</dt><dd>FINALIZED</dd>
21
<dt>ISSUED:</dt><dd>2026-02-18</dd>
22
<dt>RECORD_MODE:</dt><dd>APPEND-ONLY</dd>
23
<dt>RETENTION_PERIOD:</dt><dd>PERMANENT</dd>
24
<dt>SCHEMA_VERSION:</dt><dd>3.2</dd>
25
<dt>ACCESS_CLASSIFICATION:</dt><dd>EXECUTIVE</dd>
26
<dt>ENTRY_COUNT:</dt><dd>5</dd>
27
</dl>
28
</section>
29
<section data-section="confidentiality-notice">
30
<h2>CONFIDENTIALITY_NOTICE</h2>
31
<p>This record and all associated data, content, and information (“Material”) are proprietary to Matilon and are provided solely for authorized use. The Material may contain confidential, sensitive, or privileged information. Unauthorized access, use, disclosure, distribution, reproduction, or retention of any portion of the Material is strictly prohibited. Recipients shall protect the Material with reasonable care and use it solely for its intended purpose. The Material may not be shared, disclosed, or made accessible, in whole or in part, outside the recipient’s organization without prior written authorization from Matilon. Recipients shall ensure that any permitted access to the Material is limited to authorized personnel under equivalent confidentiality obligations.</p>
32
</section>
33
<section data-section="record-entries">
34
<h2>RECORD_ENTRIES</h2>
35
<article data-entry="MT-2026-02-18-V1-E1">
36
<dl class="entry-meta">
37
<dt>ENTRY_ID:</dt><dd>MT-2026-02-18-V1-E1</dd>
38
<dt>INGESTION_ID:</dt><dd>3C9F1A47-5D8B-4E62-B1F4-8A2E6C5D3B19</dd>
39
<dt>ENTITY:</dt><dd>FUJIFILM BIOTECHNOLOGIES</dd>
40
<dt>SUBJECT:</dt><dd>TEESSIDE SINGLE-USE BIOREACTOR CAPACITY EXPANSION</dd>
41
<dt>SUBJECT_CLASS:</dt><dd>EXPANSION</dd>
42
<dt>DOMAIN:</dt><dd>BIOMANUFACTURING CAPACITY</dd>
43
<dt>GEOGRAPHY:</dt><dd>UNITED KINGDOM</dd>
44
<dt>FUNCTIONAL_DOMAIN:</dt><dd>PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS</dd>
45
</dl>
46
<div class="entry-body">
47
<h3>DEFINITION:</h3>
48
<p>FUJIFILM Biotechnologies opened a £400 million Teesside expansion, adding 2,000 L and 5,000 L single-use bioreactors alongside new process development laboratories.</p>
49
<h3>STRUCTURE:</h3>
50
<p>End-to-end workflows now run from customer-supplied DNA through cell line development to 5,000 L scale-up, reducing external handoffs during tech transfer.</p>
51
<h3>EFFECT:</h3>
52
<p>Raises the value of standardized process definitions, facility layouts, and shared digital templates as Teesside aligns with FUJIFILM's Toyama facility.</p>
53
</div>
54
</article>
55
<article data-entry="MT-2026-02-18-V1-E2">
56
<dl class="entry-meta">
57
<dt>ENTRY_ID:</dt><dd>MT-2026-02-18-V1-E2</dd>
58
<dt>INGESTION_ID:</dt><dd>8E4A2F91-6C3D-4B57-9A2E-1F5C8D7B4A63</dd>
59
<dt>ENTITY:</dt><dd>MADE SCIENTIFIC; STREAMLINE BIO</dd>
60
<dt>SUBJECT:</dt><dd>ROBOTIC CAR-T PLATFORM INTEGRATION AND VALIDATION</dd>
61
<dt>SUBJECT_CLASS:</dt><dd>INTEGRATION</dd>
62
<dt>DOMAIN:</dt><dd>AUTOMATED CELL THERAPY SYSTEMS</dd>
63
<dt>GEOGRAPHY:</dt><dd>UNITED STATES</dd>
64
<dt>FUNCTIONAL_DOMAIN:</dt><dd>ADVANCED THERAPIES MANUFACTURING; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS</dd>
65
</dl>
66
<div class="entry-body">
67
<h3>DEFINITION:</h3>
68
<p>Made Scientific joined Streamline Bio's early adopter program to integrate and validate Streamline's AI-driven robotic platform within Made's GMP operations.</p>
69
<h3>STRUCTURE:</h3>
70
<p>New unit operations, enhanced in-process analytics, and expanded data capture characterize autonomous CAR-T steps across cycle time, robustness, and scalability.</p>
71
<h3>EFFECT:</h3>
72
<p>Concentrates early validation and integration patterns at a single CDMO site, accelerating later rollout while deepening dependence on site-specific procedures.</p>
73
</div>
74
</article>
75
<article data-entry="MT-2026-02-18-V1-E3">
76
<dl class="entry-meta">
77
<dt>ENTRY_ID:</dt><dd>MT-2026-02-18-V1-E3</dd>
78
<dt>INGESTION_ID:</dt><dd>1D6B3E84-7F92-4A58-B3C1-5E2F9A8D6C47</dd>
79
<dt>ENTITY:</dt><dd>OXFORD BIOMEDICA; BRISTOL MYERS SQUIBB</dd>
80
<dt>SUBJECT:</dt><dd>LENTIVIRAL VECTOR COMMERCIAL SUPPLY AGREEMENT</dd>
81
<dt>SUBJECT_CLASS:</dt><dd>SUPPLY</dd>
82
<dt>DOMAIN:</dt><dd>VIRAL VECTOR MANUFACTURING</dd>
83
<dt>GEOGRAPHY:</dt><dd>UNITED KINGDOM; UNITED STATES</dd>
84
<dt>FUNCTIONAL_DOMAIN:</dt><dd>PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS</dd>
85
</dl>
86
<div class="entry-body">
87
<h3>DEFINITION:</h3>
88
<p>Oxford Biomedica signed a five-year commercial supply agreement, with an extension option, to manufacture lentiviral vectors for Bristol Myers Squibb CAR-T programs.</p>
89
<h3>STRUCTURE:</h3>
90
<p>Commercial manufacturing is expected to begin in 2026, subject to regulatory approvals, across Oxford, United Kingdom and Durham, North Carolina sites.</p>
91
<h3>EFFECT:</h3>
92
<p>Requires aligned control strategies, harmonized release specifications, and quality data exchange across both sites to hold consistent commercial output through the supply term.</p>
93
</div>
94
</article>
95
<article data-entry="MT-2026-02-18-V1-E4">
96
<dl class="entry-meta">
97
<dt>ENTRY_ID:</dt><dd>MT-2026-02-18-V1-E4</dd>
98
<dt>INGESTION_ID:</dt><dd>5F2C9A18-3E7B-4D64-A8F2-6B1E5C9D3A72</dd>
99
<dt>ENTITY:</dt><dd>GEMINIBIO; TOLEMY BIO</dd>
100
<dt>SUBJECT:</dt><dd>AI-DRIVEN CUSTOM MEDIA SUPPLEMENT SERVICE INTRODUCTION</dd>
101
<dt>SUBJECT_CLASS:</dt><dd>DEPLOYMENT</dd>
102
<dt>DOMAIN:</dt><dd>BIOPROCESS MEDIA DESIGN</dd>
103
<dt>GEOGRAPHY:</dt><dd>UNITED STATES</dd>
104
<dt>FUNCTIONAL_DOMAIN:</dt><dd>PROCESS DEVELOPMENT AND MSAT; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS</dd>
105
</dl>
106
<div class="entry-body">
107
<h3>DEFINITION:</h3>
108
<p>GeminiBio and Tolemy Bio introduced aiMOS, a service applying AI/ML and multi-omics to design custom media supplements for cell therapy processes and manufacture them to cGMP standards.</p>
109
<h3>STRUCTURE:</h3>
110
<p>AI/ML modeling over multi-omics data designs custom supplements for tighter critical quality attributes and lower batch variability, reducing iterative media tuning cycles.</p>
111
<h3>EFFECT:</h3>
112
<p>Adds dataset governance and supplement change-control requirements, with model outputs needing controlled mapping into MES, CMC documentation, and release records before formulations reach GMP production.</p>
113
</div>
114
</article>
115
<article data-entry="MT-2026-02-18-V1-E5">
116
<dl class="entry-meta">
117
<dt>ENTRY_ID:</dt><dd>MT-2026-02-18-V1-E5</dd>
118
<dt>INGESTION_ID:</dt><dd>9A7E4C2F-8B5D-4163-9E2A-3F8C1B6D5E94</dd>
119
<dt>ENTITY:</dt><dd>NUCLEUS BIOLOGICS</dd>
120
<dt>SUBJECT:</dt><dd>KRAKATOA K500 POINT-OF-USE MEDIA POD LAUNCH</dd>
121
<dt>SUBJECT_CLASS:</dt><dd>DEPLOYMENT</dd>
122
<dt>DOMAIN:</dt><dd>POINT-OF-USE MEDIA SYSTEMS</dd>
123
<dt>GEOGRAPHY:</dt><dd>UNITED STATES</dd>
124
<dt>FUNCTIONAL_DOMAIN:</dt><dd>AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS; ADVANCED THERAPIES MANUFACTURING</dd>
125
</dl>
126
<div class="entry-body">
127
<h3>DEFINITION:</h3>
128
<p>Nucleus Biologics launched Krakatoa K500, a pod-based single-use system producing 35–500 L of sterile media and buffers at the point of use.</p>
129
<h3>STRUCTURE:</h3>
130
<p>QR-code execution, inline pH and conductivity monitoring, and automated digital batch records reduce centralized liquid prep and cold storage while preserving traceability.</p>
131
<h3>EFFECT:</h3>
132
<p>Shifts media and buffer preparation to the point of use, reopening qualification boundaries, cleanroom layouts, and validation scope as liquid prep moves beside the bioreactor.</p>
133
</div>
134
</article>
135
</section>
136
<section data-section="disclaimer-of-liability">
137
<h2>DISCLAIMER_OF_LIABILITY</h2>
138
<p>This record and all associated data, content, analyses, and information (“Material”) are provided by Matilon for informational and internal decision-support purposes only. Matilon makes no representations or warranties, express or implied, as to the accuracy, completeness, timeliness, reliability, or fitness for any particular purpose of the Material. The Material does not constitute legal, financial, technical, or strategic advice, and shall not be relied upon as the sole basis for any decision, action, or omission. Any use of or reliance on the Material is undertaken at the recipient’s sole risk and discretion. To the fullest extent permitted by applicable law, Matilon disclaims all liability for any direct, indirect, incidental, consequential, or special damages arising out of or in connection with the use of, or inability to use, the Material, including any errors or omissions therein. Matilon assumes no obligation to update, correct, revise, or supplement the Material, the use and distribution of which are governed by the Matilon Terms of Service and the policies incorporated thereunder.</p>
139
</section>
140
<footer>
141
<p>MT-2026-02-18-V1 · V1.0 · 2026-02-18 · © MATILON · CONFIDENTIAL</p>
142
</footer>
143
</body>
144
</html>
MT-2026-02-18-V1.txttext/plain; charset=UTF-8 · 118 LINES · 6.8 KB
MATILON RESEARCH
RECORD_CONTROL
TYPE: INTELLIGENCE
RECORD_ID: MT-2026-02-18-V1
PRECEDING_RECORD: MT-2026-02-11-V1
RECORD_SIGNATURE: 7A2E9C4F-3B81-4D56-A9E3-2F7C8B1D5E04
VERSION: 1.0
STATUS: FINALIZED
ISSUED: 2026-02-18
RECORD_MODE: APPEND-ONLY
RETENTION_PERIOD: PERMANENT
SCHEMA_VERSION: 3.2
ACCESS_CLASSIFICATION: EXECUTIVE
ENTRY_COUNT: 5
CONFIDENTIALITY_NOTICE
This record and all associated data, content, and information (“Material”) are proprietary to Matilon and are provided solely for authorized use. The Material may contain confidential, sensitive, or privileged information. Unauthorized access, use, disclosure, distribution, reproduction, or retention of any portion of the Material is strictly prohibited. Recipients shall protect the Material with reasonable care and use it solely for its intended purpose. The Material may not be shared, disclosed, or made accessible, in whole or in part, outside the recipient’s organization without prior written authorization from Matilon. Recipients shall ensure that any permitted access to the Material is limited to authorized personnel under equivalent confidentiality obligations.
RECORD_ENTRIES
ENTRY_ID: MT-2026-02-18-V1-E1
INGESTION_ID: 3C9F1A47-5D8B-4E62-B1F4-8A2E6C5D3B19
ENTITY: FUJIFILM BIOTECHNOLOGIES
SUBJECT: TEESSIDE SINGLE-USE BIOREACTOR CAPACITY EXPANSION
SUBJECT_CLASS: EXPANSION
DOMAIN: BIOMANUFACTURING CAPACITY
GEOGRAPHY: UNITED KINGDOM
FUNCTIONAL_DOMAIN: PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS
DEFINITION:
FUJIFILM Biotechnologies opened a £400 million Teesside expansion, adding 2,000 L and 5,000 L single-use bioreactors alongside new process development laboratories.
STRUCTURE:
End-to-end workflows now run from customer-supplied DNA through cell line development to 5,000 L scale-up, reducing external handoffs during tech transfer.
EFFECT:
Raises the value of standardized process definitions, facility layouts, and shared digital templates as Teesside aligns with FUJIFILM's Toyama facility.
ENTRY_ID: MT-2026-02-18-V1-E2
INGESTION_ID: 8E4A2F91-6C3D-4B57-9A2E-1F5C8D7B4A63
ENTITY: MADE SCIENTIFIC; STREAMLINE BIO
SUBJECT: ROBOTIC CAR-T PLATFORM INTEGRATION AND VALIDATION
SUBJECT_CLASS: INTEGRATION
DOMAIN: AUTOMATED CELL THERAPY SYSTEMS
GEOGRAPHY: UNITED STATES
FUNCTIONAL_DOMAIN: ADVANCED THERAPIES MANUFACTURING; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS
DEFINITION:
Made Scientific joined Streamline Bio's early adopter program to integrate and validate Streamline's AI-driven robotic platform within Made's GMP operations.
STRUCTURE:
New unit operations, enhanced in-process analytics, and expanded data capture characterize autonomous CAR-T steps across cycle time, robustness, and scalability.
EFFECT:
Concentrates early validation and integration patterns at a single CDMO site, accelerating later rollout while deepening dependence on site-specific procedures.
ENTRY_ID: MT-2026-02-18-V1-E3
INGESTION_ID: 1D6B3E84-7F92-4A58-B3C1-5E2F9A8D6C47
ENTITY: OXFORD BIOMEDICA; BRISTOL MYERS SQUIBB
SUBJECT: LENTIVIRAL VECTOR COMMERCIAL SUPPLY AGREEMENT
SUBJECT_CLASS: SUPPLY
DOMAIN: VIRAL VECTOR MANUFACTURING
GEOGRAPHY: UNITED KINGDOM; UNITED STATES
FUNCTIONAL_DOMAIN: PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS
DEFINITION:
Oxford Biomedica signed a five-year commercial supply agreement, with an extension option, to manufacture lentiviral vectors for Bristol Myers Squibb CAR-T programs.
STRUCTURE:
Commercial manufacturing is expected to begin in 2026, subject to regulatory approvals, across Oxford, United Kingdom and Durham, North Carolina sites.
EFFECT:
Requires aligned control strategies, harmonized release specifications, and quality data exchange across both sites to hold consistent commercial output through the supply term.
ENTRY_ID: MT-2026-02-18-V1-E4
INGESTION_ID: 5F2C9A18-3E7B-4D64-A8F2-6B1E5C9D3A72
ENTITY: GEMINIBIO; TOLEMY BIO
SUBJECT: AI-DRIVEN CUSTOM MEDIA SUPPLEMENT SERVICE INTRODUCTION
SUBJECT_CLASS: DEPLOYMENT
DOMAIN: BIOPROCESS MEDIA DESIGN
GEOGRAPHY: UNITED STATES
FUNCTIONAL_DOMAIN: PROCESS DEVELOPMENT AND MSAT; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS
DEFINITION:
GeminiBio and Tolemy Bio introduced aiMOS, a service applying AI/ML and multi-omics to design custom media supplements for cell therapy processes and manufacture them to cGMP standards.
STRUCTURE:
AI/ML modeling over multi-omics data designs custom supplements for tighter critical quality attributes and lower batch variability, reducing iterative media tuning cycles.
EFFECT:
Adds dataset governance and supplement change-control requirements, with model outputs needing controlled mapping into MES, CMC documentation, and release records before formulations reach GMP production.
ENTRY_ID: MT-2026-02-18-V1-E5
INGESTION_ID: 9A7E4C2F-8B5D-4163-9E2A-3F8C1B6D5E94
ENTITY: NUCLEUS BIOLOGICS
SUBJECT: KRAKATOA K500 POINT-OF-USE MEDIA POD LAUNCH
SUBJECT_CLASS: DEPLOYMENT
DOMAIN: POINT-OF-USE MEDIA SYSTEMS
GEOGRAPHY: UNITED STATES
FUNCTIONAL_DOMAIN: AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS; ADVANCED THERAPIES MANUFACTURING
DEFINITION:
Nucleus Biologics launched Krakatoa K500, a pod-based single-use system producing 35–500 L of sterile media and buffers at the point of use.
STRUCTURE:
QR-code execution, inline pH and conductivity monitoring, and automated digital batch records reduce centralized liquid prep and cold storage while preserving traceability.
EFFECT:
Shifts media and buffer preparation to the point of use, reopening qualification boundaries, cleanroom layouts, and validation scope as liquid prep moves beside the bioreactor.
DISCLAIMER_OF_LIABILITY
This record and all associated data, content, analyses, and information (“Material”) are provided by Matilon for informational and internal decision-support purposes only. Matilon makes no representations or warranties, express or implied, as to the accuracy, completeness, timeliness, reliability, or fitness for any particular purpose of the Material. The Material does not constitute legal, financial, technical, or strategic advice, and shall not be relied upon as the sole basis for any decision, action, or omission. Any use of or reliance on the Material is undertaken at the recipient’s sole risk and discretion. To the fullest extent permitted by applicable law, Matilon disclaims all liability for any direct, indirect, incidental, consequential, or special damages arising out of or in connection with the use of, or inability to use, the Material, including any errors or omissions therein. Matilon assumes no obligation to update, correct, revise, or supplement the Material, the use and distribution of which are governed by the Matilon Terms of Service and the policies incorporated thereunder.
MT-2026-02-18-V1 · V1.0 · 2026-02-18 · © MATILON · CONFIDENTIAL
View complete specimen →

05 / EXTRACTION

Record Extraction

Matilon Research records are extracted under a published specification and authorized for ingestion and retention within recipient systems.

EXTRACTION PASSMT-2026-02-18-V1 · SCHEMA v3.2
record.type = "INTELLIGENCE"
record.record_id = "MT-2026-02-18-V1"
record.preceding_record = "MT-2026-02-11-V1"
record.record_signature = "7A2E9C4F-3B81-4D56-A9E3-2F7C8B1D5E04"
record.version = "1.0"
record.status = "FINALIZED"
record.issued = "2026-02-18"
record.record_mode = "APPEND-ONLY"
record.retention_period = "PERMANENT"
record.schema_version = "3.2"
record.access_classification = "EXECUTIVE"
record.entry_count = 5
record.entry[0].entry_id = "MT-2026-02-18-V1-E1"
record.entry[0].ingestion_id = "3C9F1A47-5D8B-4E62-B1F4-8A2E6C5D3B19"
record.entry[0].entity = ["FUJIFILM BIOTECHNOLOGIES"]
record.entry[0].subject = "TEESSIDE SINGLE-USE BIOREACTOR CAPACITY EXPANSION"
record.entry[0].subject_class = "EXPANSION"
record.entry[0].domain = "BIOMANUFACTURING CAPACITY"
record.entry[0].geography = ["UNITED KINGDOM"]
record.entry[0].functional_domain = ["PROCESS DEVELOPMENT AND MSAT", "TECH TRANSFER AND CMC PROGRAM LEADERSHIP", "EXECUTIVE MANUFACTURING AND TECHOPS"]
record.entry[0].body.definition = "FUJIFILM Biotechnologies opened a £400 million Teesside expansion, adding 2,000 L and 5,000 L single-use bioreactors alongside new process development laboratories."
record.entry[0].body.structure = "End-to-end workflows now run from customer-supplied DNA through cell line development to 5,000 L scale-up, reducing external handoffs during tech transfer."
record.entry[0].body.effect = "Raises the value of standardized process definitions, facility layouts, and shared digital templates as Teesside aligns with FUJIFILM's Toyama facility."
record.entry[1].entry_id = "MT-2026-02-18-V1-E2"
record.entry[1].ingestion_id = "8E4A2F91-6C3D-4B57-9A2E-1F5C8D7B4A63"
record.entry[1].entity = ["MADE SCIENTIFIC", "STREAMLINE BIO"]
record.entry[1].subject = "ROBOTIC CAR-T PLATFORM INTEGRATION AND VALIDATION"
record.entry[1].subject_class = "INTEGRATION"
record.entry[1].domain = "AUTOMATED CELL THERAPY SYSTEMS"
record.entry[1].geography = ["UNITED STATES"]
record.entry[1].functional_domain = ["ADVANCED THERAPIES MANUFACTURING", "AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS"]
record.entry[1].body.definition = "Made Scientific joined Streamline Bio's early adopter program to integrate and validate Streamline's AI-driven robotic platform within Made's GMP operations."
record.entry[1].body.structure = "New unit operations, enhanced in-process analytics, and expanded data capture characterize autonomous CAR-T steps across cycle time, robustness, and scalability."
record.entry[1].body.effect = "Concentrates early validation and integration patterns at a single CDMO site, accelerating later rollout while deepening dependence on site-specific procedures."
record.entry[2].entry_id = "MT-2026-02-18-V1-E3"
record.entry[2].ingestion_id = "1D6B3E84-7F92-4A58-B3C1-5E2F9A8D6C47"
record.entry[2].entity = ["OXFORD BIOMEDICA", "BRISTOL MYERS SQUIBB"]
record.entry[2].subject = "LENTIVIRAL VECTOR COMMERCIAL SUPPLY AGREEMENT"
record.entry[2].subject_class = "SUPPLY"
record.entry[2].domain = "VIRAL VECTOR MANUFACTURING"
record.entry[2].geography = ["UNITED KINGDOM", "UNITED STATES"]
record.entry[2].functional_domain = ["PROCESS DEVELOPMENT AND MSAT", "TECH TRANSFER AND CMC PROGRAM LEADERSHIP", "EXECUTIVE MANUFACTURING AND TECHOPS"]
record.entry[2].body.definition = "Oxford Biomedica signed a five-year commercial supply agreement, with an extension option, to manufacture lentiviral vectors for Bristol Myers Squibb CAR-T programs."
record.entry[2].body.structure = "Commercial manufacturing is expected to begin in 2026, subject to regulatory approvals, across Oxford, United Kingdom and Durham, North Carolina sites."
record.entry[2].body.effect = "Requires aligned control strategies, harmonized release specifications, and quality data exchange across both sites to hold consistent commercial output through the supply term."
record.entry[3].entry_id = "MT-2026-02-18-V1-E4"
record.entry[3].ingestion_id = "5F2C9A18-3E7B-4D64-A8F2-6B1E5C9D3A72"
record.entry[3].entity = ["GEMINIBIO", "TOLEMY BIO"]
record.entry[3].subject = "AI-DRIVEN CUSTOM MEDIA SUPPLEMENT SERVICE INTRODUCTION"
record.entry[3].subject_class = "DEPLOYMENT"
record.entry[3].domain = "BIOPROCESS MEDIA DESIGN"
record.entry[3].geography = ["UNITED STATES"]
record.entry[3].functional_domain = ["PROCESS DEVELOPMENT AND MSAT", "AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS"]
record.entry[3].body.definition = "GeminiBio and Tolemy Bio introduced aiMOS, a service applying AI/ML and multi-omics to design custom media supplements for cell therapy processes and manufacture them to cGMP standards."
record.entry[3].body.structure = "AI/ML modeling over multi-omics data designs custom supplements for tighter critical quality attributes and lower batch variability, reducing iterative media tuning cycles."
record.entry[3].body.effect = "Adds dataset governance and supplement change-control requirements, with model outputs needing controlled mapping into MES, CMC documentation, and release records before formulations reach GMP production."
record.entry[4].entry_id = "MT-2026-02-18-V1-E5"
record.entry[4].ingestion_id = "9A7E4C2F-8B5D-4163-9E2A-3F8C1B6D5E94"
record.entry[4].entity = ["NUCLEUS BIOLOGICS"]
record.entry[4].subject = "KRAKATOA K500 POINT-OF-USE MEDIA POD LAUNCH"
record.entry[4].subject_class = "DEPLOYMENT"
record.entry[4].domain = "POINT-OF-USE MEDIA SYSTEMS"
record.entry[4].geography = ["UNITED STATES"]
record.entry[4].functional_domain = ["AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS", "ADVANCED THERAPIES MANUFACTURING"]
record.entry[4].body.definition = "Nucleus Biologics launched Krakatoa K500, a pod-based single-use system producing 35–500 L of sterile media and buffers at the point of use."
record.entry[4].body.structure = "QR-code execution, inline pH and conductivity monitoring, and automated digital batch records reduce centralized liquid prep and cold storage while preserving traceability."
record.entry[4].body.effect = "Shifts media and buffer preparation to the point of use, reopening qualification boundaries, cleanroom layouts, and validation scope as liquid prep moves beside the bioreactor."

Authorized recipient systems

Document and Records

  • Records retention and archive systems
  • Enterprise content and document management
  • Internal knowledge and reference libraries

Sourcing and Supplier

  • Supplier qualification and vendor master
  • Vendor risk and diligence repositories
  • Source-to-pay and procurement systems
  • Sourcing event and tender workspaces

Program and Technical

  • Program and portfolio management systems
  • Architecture and technology review files
  • Engineering and operations document systems

Executive and Governance

  • Steering and governance committee records
  • Investment and capital review files
  • Executive briefing and reporting systems
  • Internal collaboration and distribution

Data License Agreement →

View extraction specification →

06 / RECORDS

Records

Matilon Research records adhere to a canonical schema defining record control, entry structure, and field anchors. Records are issued in chained sequence, retained permanently under append-only governance, and extracted via a published specification.

07 / SOLUTIONS